ARCHIVES

Gilotrif Increases PFS Compared to Erlotinib In LUX-Lung 8 Phase III Head-to-Head Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 10 | October 31, 2014

Download PDF Visit The Full Archive

Related Articles

In Brief: ACS Begins Narrowing List of Job Applicants; IL-2 Gets BRM Ok; Pitot Resigns McArdle Post

January 31, 1992

More DCT Concepts Approved By Advisors

July 10, 1992

US Oncology Renegotiates Agreements To Operate Under Net Earnings Model.

March 30, 2001

Sanding Study Section For Cancer Control Grants Needed, Board Says

May 17, 1985

Frederick RFP Available Oct. 22; Three Four May Challenge L-B

August 27, 1976

President’s Budget Takes Care If R01s, P01s, Fattens Up NTP, Devastates Construction Grants

February 1, 1980